Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
The lack of robust immunocompetent animal models permissive
2019-08-05
The lack of robust immunocompetent animal models permissive for HCV makes it hard to assess if the quantity and quality of vaccine-induced immunity is sufficient to confer protection. Thus, it is difficult to predict to what extent antibody responses induced by current vaccination approaches, includ
-
Ko 143 calculator The interface between the E ligase
2019-08-05
The interface between the E3 ligase and the E2 enzyme can vary, and ZNF451 and SP-RING ligases stabilize this interaction via noncovalent binding to a scaffold SUMO (SUMOB) on the backside of the E2 (Cappadocia et al., 2015; Eisenhardt et al., 2015; Streich & Lima, 2016). By contrast, RanBP2 does no
-
Tamoxifen is included in the treatment
2019-08-05
Tamoxifen is included in the treatment protocol of ER+ breast carcinoma patients routinely. Although tamoxifen improves patients\' survival, unfortunately a large number of ER+ patients don\'t response to tamoxifen treatment (Yager and Davidson, 2006). Detection of molecular markers which could take
-
Analysis of Table shows that compound b
2019-08-05
Analysis of Table 1 shows that compound 7b, in which the biphenyl scaffold does not bear any substituent, displays its inhibitory potency in the micromolar range (IC50 = 11 μM). If the amide bridge is moved from position 1 to 3 of the biphenyl system, product 7c is yielded, whose potency is about 4
-
MTX and MTXPGs block the activity of the key enzyme
2019-08-05
MTX and MTXPGs block the activity of the key enzyme DHFR (Fig. 1), which converts folates to their active forms – dihydrofolate (DHF) and tetrahydrofolate (THF). MTXPGs also potently inhibit thymidylate synthase (TS). Furthermore, during dTMP synthesis, TS utilizes the cofactor 5,10-methylene THF, w
-
We show that direct contact with
2019-08-05
We show that direct contact with MSCs is necessary and sufficient to induce DDR2 upregulation in breast cancer cells. DDR2 expression in MSC is required for collagen deposition and leads to increased DDR2 expression and activation in breast cancer cells. This paracrine-autocrine MSC-cancer cell axis
-
In a recent study Tomkins et al analyzed the protein
2019-08-05
In a recent study, Tomkins et al. [7] analyzed the protein-protein interaction network of ROCO proteins. Based on a database analysis, and only taking into account interactions reported in at least two peer-reviewed papers and/or confirmed by two different methods, 113 interactors were revealed for
-
br CDKs as Direct Coactivators of Proinflammatory Transcript
2019-08-05
CDKs as Direct Coactivators of Proinflammatory Transcription Factors CDKs fuel inflammation by triggering the function of proinflammatory transcription factors such as NF-κB, STAT3, and AP-1. This is achieved at two levels because CDKs can affect gene expression by targeting global transcription
-
The synthetic route of R changed derivatives is shown in
2019-08-05
The synthetic route of R-changed derivatives is shown in . Compounds – were prepared from commercially available 4-nitro-1-indazole (). After same two steps with , the N-substituted indazole of was produced using the Suzuki reaction in a good yield (85%). Reduction of was performed using Pd/C, and t
-
Unlike CRM exportins Cse and Xpot lack a C extension
2019-08-05
Unlike CRM1, exportins Cse1 and Xpot lack a C-extension and instead rely primarily on changes in HEAT-repeat conformation and direct Ran-cargo contacts to ensure low cargo-binding affinity in the cytosol and cooperative assembly of the exportin/Ran/cargo complex in the nucleus (Cook et al., 2005, Co
-
br Clinical trials of CRM inhibitors KPT clinical trials hav
2019-08-05
Clinical trials of CRM1 inhibitors KPT-330 clinical trials have been initiated with promising very early results. One trial includes patients with advanced solid tumors whose disease has progressed after at least one prior therapy for metastatic disease (NCT01607905). Another trial includes patie
-
br Diseases which have been
2019-08-05
Diseases which have been treated with proteins linked to HSA A number of therapeutic products conjugated to HSA have now been approved for clinical use (Table 2). For example, fatty YAP-TEAD Inhibitor 1 derivatives of human insulin bound to HSA have applications in the treatment of diabetes while
-
br These component origins have been chosen as they are
2019-08-05
These component origins have been chosen as they GDC-0349 calculator are well-defined options related to developing with components (see for example Morisio and Torchiano (2002); Carney and Long (2000) and Gacek and Arief (2004)). The individual component origins (COTS, OSS, in-house developed co
-
The classification of CK substrates based on
2019-08-05
The classification of CK2 substrates based on active enzyme subunit composition provides a framework for understanding the regulatory function of CK2β subunit. However, few experiments exist that functionally explore such classification [17], [18], [19], [20], [21], [22], [23]; this reflects practic
-
br Conflict of interest br Acknowledgements This study
2019-08-05
Conflict of interest Acknowledgements This study was supported by the National Natural Science Foundation of China (No.31571839), the Chinese Ministry Program for New Century Excellent Talents in University (NCET-12-0865), and Special Fund for Agro-scientific Research in the Public Interest (N
14829 records 975/989 page Previous Next First page 上5页 971972973974975 下5页 Last page